%0 Journal Article
%T CRISPR/Cas9 engineering offers new opportunities to model pancreatic ductal adenocarcinoma development
%A Claus J£¿rgensen
%A Elizabeth K. J. Hogg
%J SCIE-indexed Journal
%D 2016
%R 10.21037/8956
%X Pancreatic ductal adenocarcinoma (PDAC) is a dismal disease. The 5-year survival is below 5%, which is due to a combination of aggressive disease progression, late diagnosis and limited treatment options (1). Consequently, PDAC is predicted to be the second-largest contributor to cancer related deaths by 2020 (2). New approaches and models to accelerate therapeutic development and improve patient outcome are therefore urgently needed
%U http://tcr.amegroups.com/article/view/8956/html